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E-mail: c.a.h.h.daemen@umcg.nlA first-in-human phase I trial of Vvax001, an alphavirus-
based therapeutic cancer vaccine against human papilloma-
virus (HPV)-induced cancers was performed assessing
immunological activity, safety, and tolerability. Vvax001 con-
sists of replication-incompetent Semliki Forest virus replicon
particles encoding HPV16-derived antigens E6 and E7.
Twelve participants with a history of cervical intraepithelial
neoplasia were included. Four cohorts of three participants
were treated per dose level, ranging from 5  105 to 2.5 
108 infectious particles per immunization. The participants
received three immunizations with a 3-week interval. For im-
mune monitoring, blood was drawn before immunization
and 1 week after the second and third immunization. Immu-
nization with Vvax001 was safe and well tolerated, with only
mild injection site reactions, and resulted in both CD4+ and
CD8+ T cell responses against E6 and E7 antigens. Even the
lowest dose of 5  105 infectious particles elicited E6/E7-spe-
cific interferon (IFN)-g responses in all three participants in
this cohort. Overall, immunization resulted in positive vac-
cine-induced immune responses in 12 of 12 participants in
one or more assays performed. In conclusion, Vvax001 was
safe and induced immune responses in all participants. These
data strongly support further clinical evaluation of Vvax001
as a therapeutic vaccine in patients with HPV-related malig-
nancies.
INTRODUCTION
Cancer vaccines based on viral RNA replicons are gaining more
and more interest because of their safety and efficacy to induce
strong and long-lasting immune responses.1–3 In this clinical trial,
we explored the application of an RNA replicon vaccine based on
Semliki Forest virus (SFV). Immunization with these replication-
defective SFV replicon particles4 has been shown to lead to high,Mo
This is an open access article under the CC BY-Nshort-term expression of heterologous proteins,5 resulting in strong
immune responses in animal models against a variety of viral and
tumor antigens.6–11 These promising preclinical studies warranted
clinical studies of this vector platform.12
SFV belongs to the Alphavirus genus. The genome of wild-type
SFV consists of a single-stranded, positive sense RNA encoding
non-structural proteins that are responsible for transcription and
replication of viral RNA, and structural proteins, i.e., the capsid
protein and envelope glycoproteins. In recombinant SFV (rSFV)
vectors, the structural genes are deleted from the SFV genome
and replaced by the gene of interest. This genome is packaged in
a virus particle consisting of a nucleocapsid and a membrane en-
velope. The membrane envelope contains the glycoproteins E1,
E2, and E3, which are involved in receptor recognition and mem-
brane fusion. Upon infection of cells by rSFV replicon particles
and fusion of the viral membrane with the endosomal membrane,
the RNA genome is delivered into the cytoplasm, where it repli-
cates and the gene of interest is expressed. The high immunoge-
nicity of SFV-based vaccines is most likely due to the self-ampli-
fying nature of the SFV replicase, resulting in high transgene
expression and a high number of copies of viral RNA transcripts
stimulating innate immune responses. The RNA transcripts signal
innate immunity through RNA sensing by Toll-like receptor (TLR)
3, TLR7, TLR8, MDA-5, RIG-I, and protein kinase R for a type I
interferon (IFN) response. Expression is transient, as infected cellslecular Therapy Vol. 29 No 2 February 2021 ª 2020 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Baseline Characteristics of the Participants




1 5.0  105
36 HPV 16 CIN 3 LETZ
002 36 HPV 16 CIN 3 LETZ
003 28 HPV 16 CIN 3 LETZ
004
2 5.0  106
41 HPV 16 CIN 3 LETZ
005 33 HPV 16 CIN 3 LETZ
006a 46 – CIN 2 LETZ
007
3 5.0  107
53 HPV 16 CIN 3 LETZ
008 35 HPV 16 CIN 2 LETZ
010 25 HPV 18 CIN 3 LETZ
011
4 2.5  108
41 HPV 16 CIN 3 LETZ
012 57 HPV 16 CIN 2 LETZ
013a 42 – CIN 3 LETZ
CIN, cervical intraepithelial neoplasia; LETZ, loop excision of the transformation zone.
aParticipant tested negative for high-risk human papilloma virus (HPV).
Molecular Therapy
Please cite this article in press as: Komdeur et al., First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced
Cancers, Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.11.002undergo apoptotic cell death, resulting in cross-priming for adap-
tive immunity. Furthermore, no new progeny virus particles are
produced because the RNA genome lacks the genes encoding the
structural proteins. Hence, replication-defective rSFV replicon par-
ticles are also termed “suicide” particles.1,4,5
This SFV-based vector platform was used to develop a therapeutic
vaccine against human papillomavirus (HPV)-induced can-
cers.9,13–15 HPV is the causative agent for cervical cancer,16–18
the fourth most common cause of cancer death among women
worldwide,19 as well as other genital cancers and oropharyngeal
cancer.16 Of all HPV subtypes, HPV16 is most commonly associ-
ated with (pre-)malignant disease of the cervix.20 The risk of devel-
oping malignancies after infection with HPV is largely due to the
ability of high-risk HPVs to transform epithelial cells by inte-
grating viral DNA into the host cell genome. This integration leads
to constitutive expression of the viral proteins E6 and E7, which is
required for the maintenance of the transformed phenotype.21,22
Therefore, these oncoproteins are potential targets for immuno-
therapeutic intervention strategies against HPV-related infections
or malignancies.
Several therapeutic approaches to combat HPV-related malignancies
are being pursued in clinical trials, showing promising results in early
phase trials. These include vaccinations based on bacterial/viral vec-
tors, peptides/proteins, nucleic acids, and dendritic cells,23 and
some of them are currently being evaluated in phase II trials. We
developed an rSFV-based therapeutic vaccine, Vvax001, encoding a
fusion protein of HPV16 E6 and E7. Herein, we report the results
of a first-in-human clinical trial with our SFV-based vector vaccine.
In this phase I study, our objective was to evaluate the immunoge-
nicity, safety, and tolerability of Vvax001.2 Molecular Therapy Vol. 29 No 2 February 2021RESULTS
Participant Characteristics
The evaluable population used for both the efficacy and safety ana-
lyses consisted of 12 participants (Table 1). The median age at the
time of inclusion was 38.5 years (range, 25–57). All participants
had a medical history of cervical intraepithelial neoplasia (CIN), for
which they received a loop excision of the transformation zone
(LETZ). Three participants had CIN 2 and nine participants had
CIN 3. Nine participants had an HPV16-positive lesion, one partici-
pant had an HPV18-positive lesion, and two participants had a high-
risk HPV-negative lesion.Immunization with Vvax001 Was Safe and Well Tolerated
Most treatment-emergent adverse events (TEAEs) considered related
to study treatment were injection site reaction, injection site hema-
toma, peripheral edema, chills, myalgia, back pain, and lymphade-
nopathy (swelling of lymph nodes in groins) (Table S1). The occur-
rence of adverse events did not appear to be correlated to dose level
or time point. With the exception of one moderate injection site reac-
tion, all reported TEAEs were mild and mainly restricted to myalgia
and injection site reactions. There were no reports of TEAEs with a
CTC grade 3 or 4 and no dose-limiting toxicity was noted. All four
dose levels of Vvax001 investigated in this study were safe and well
tolerated.VVax001 Immunizations Did Not Induce Significant Changes in
Lymphocyte Subsets
To assess changes in lymphocyte populations before and after immu-
nizations, peripheral blood mononuclear cells (PBMCs) were
analyzed for the distribution of T cells, B cells, and natural killer
(NK) cells. The percentages of CD3+ T cells, CD4+ T cells, CD8+
A
C D
B Figure 1. HPV16 E6- and E7-Specific T Cell
Responses Elicited by Vvax001 Immunization
PBMCs isolated from blood samples obtained before
(time point A) and after the second (time point B) and
the third (time point C) immunization were analyzed
for the presence of IFN-g-secreting cells by ELISPOT.
The number of specific spots (per million PBMCs)
following stimulation with HPV16 E6 (blue) or E7
peptide (green) pools are depicted. IFN-g responses
at different dose levels are presented: (A) cohort 1,
5  105 IP; (B) cohort 2, 5  106 IP; (C) cohort 3, 5 
107 IP; (D) cohort 4, 2.5  108 IP. The number of
specific spots were calculated by subtracting the
mean number of spots + 2  SD of the medium-only
control from the mean number of spots in experi-
mental wells. An asterisk indicates a positive vaccine-
induced response (as defined in Materials and
Methods).
www.moleculartherapy.org
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ble to those observed before immunization (Table S2), except for one
unexplained low percent of CD3+ T cells at time point A for partici-
pant 010.
Vvax001 Induced Strong HPV16 E6- and E7-Specific IFN-g
Responses
To study the cellular immune responses induced by Vvax001, PBMCs
isolated before and after the second and third immunizations were
analyzed for the presence of HPV16-specific IFN-g-producing cells
by IFN-g enzyme-linked immunospot (ELISPOT), the primary
endpoint of the study. Vaccine-induced antigen-specific responses
were calculated on the basis of predefined criteria, as mentioned in
the Materials and Methods.
In all participants, prior to the first immunization (time point A), no
or only a few HPV16 E6- and/or E7-specific IFN-g-producing T cells
were detected in the PBMCs (Figure 1). Surprisingly, already with the
lowest dose (5 105 infectious particles [IP] Vvax001 per immuniza-
tion), positive vaccine-induced T cell responses were detected in all
three participants in this dose group (Figure 1A). After two immuni-
zations, HPV16 E6/E7-specific IFN-g-producing T cells were detect-
able in 5 of 12 participants. After three immunizations, positive vac-
cine-induced HPV16 E6/E7-specific T cell responses were present in
10 of 12 participants (Figure 1). The overall response against E6 an-
tigen seemed stronger than that against E7 in responding participants,
with an exception in participant 010, who exhibited a higher E7-spe-
cific response than E6 response.
Of note, the total number of IFN-g spots in the medium control cul-
tures (without in vitro restimulation with E6 or E7 peptides) with thetwo higher dosages markedly increased following both the second and
third immunizations (Figure S1).
Altogether, these findings demonstrate that Vvax001 was able to
induce HPV16 E6 and/or E7-specific T cell response.
Both CD4+ and CD8+ T Cells Contributed to IFN-g Responses
Induced by Vvax001
On the basis of these positive vaccine-induced IFN-g responses
observed in the ELISPOT assay, we were interested in further inves-
tigating the type of T cell subsets contributing to these IFN-g re-
sponses. For this, PBMCs from post-immunization blood samples
were stimulated with E6 or E7 peptide pools for 3 days. Subsequently,
CD4+ and CD8+ T cells were isolated by magnetic separation and an
ELISPOT assay was performed. Due to shortage of samples, we could
not evaluate samples from all participants and conducted this assay
with samples from participants 003, 004, 007, 008, 010, 011, 012,
and 013. The vaccine elicited activation of both CD4+ and CD8+
T cells specific for E6 and/or E7 (Figure 2; Figure S2).
Overall, this analysis demonstrated that within the HPV16-specific
T cells activated by Vvax001 immunization, both CD4+ and CD8+
T cells contributed to the production of IFN-g.
Vvax001 Induced Proliferation of T Cells
Since we observed induction of cellular immune responses upon im-
munization in the participants, we speculated that these immune re-
sponses could be due to expansion of T cells. Therefore, we evaluated
the proliferative capacity of HPV16-specific CD4+ and CD8+ T cells.
PBMCs obtained before and after immunizations were stimulated





Figure 2. IFN-g Production by CD4+ and CD8+ T Cells
Following stimulation of PBMCs with HPV16 E6 (blue) or E7 peptide (green) pools for 3 days, CD4+ and CD8+ T cells were magnetically sorted and analyzed for the presence
of IFN-g-secreting cells by ELISPOT. Shown are the number of specific spots per million of the respective (CD4+ or CD8+ T) cells: (A) cohort 1, 5 105 IP; (B) cohort 2, 5 106
IP; (C) cohort 3, 5 107 IP; (D) cohort 4, 2.5 108 IP. The number of specific spots were calculated by subtracting the mean number of spots + 2 SD of the medium-only
control from the mean number of spots in experimental wells. All tested samples from the participants were from time point C, except for participant 011, whose sample was
from time point B. n.d., not determined
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on the pre-defined criteria, positive, vaccine-induced proliferation of
CD8+ T cells or CD4+ T cells could be detected in the PBMCs of two
and four participants, respectively (Figure S3B; Table 2). For this
initial analysis of Ki67+ CD4+ and CD8+ T cells, a restricted gating
on the lymphocytes was used (Figure S3A). However, we observed
that immunization, especially with higher doses, induced a popula-
tion, which was to the right of the previously gated lymphocyte pop-
ulation. Based on this observation in the forward light scatter (FSC)
versus side light scatter (SSC) fluorescence-activated cell sorting
(FACS) plot, we then gated such as to include this population (Fig-
ure 3A). A closer look revealed that there was a higher rate of prolif-
eration of especially CD4+ T cells, particularly in participants immu-
nized with the two highest doses (5  107 and 2.5  108 IP) of
Vvax001 (Figures 3B and 3C). This high proliferative response was
observed in both stimulated (i.e., stimulated with E6 or E7 peptides)4 Molecular Therapy Vol. 29 No 2 February 2021and unstimulated conditions. These results correlated with the ELI-
SPOT results conducted with whole PBMCs as well as separated
CD4+ and CD8+ T cells. In the highest dose (2.5  108 IP
Vvax001) cohort, the percentages of Ki67+ CD4+ T cells after immu-
nization were higher than 10%, even increasing up to 25.5% for
participant 013. This increase was seen only upon immunization,
implying that it was vaccine induced. In line with the ELISPOT re-
sults, there seems to be a trend toward a dose-dependent, vaccine-
induced proliferation of CD4+ T cells and, to a lesser extent, of
CD8+ T cells. This high proliferative response appeared to be more
pronounced upon a 5-day culture of PBMCs and independent of
in vitro restimulation with E6 or E7 peptide.
Vvax001 Generated Strong Type 1 Cytokine Responses
As we found a higher rate of proliferation of CD4+ T cells, we further
investigated the different types of cytokine responses generated upon
Table 2. Percentage of HPV16 E6,7-Specific Proliferating (Ki67+) CD4+ and CD8+ T Cells
Cohort/Dose Participant ID
HPV16 E6+E7-Specific T Cells
% Ki67+CD4+ T Cells % Ki67+CD8+ T Cells
A B C A B C
Cohort 1,
5.0  105 IP
001 0.23 0.00 0.09 0.23 0.00 0.12
002 0.08 0.02 0.19 0.12 0.06 0.23
003 0.00 0.03 0.03 0.00 0.22a 0.04
Cohort 2,
5.0  106 IP
004 0.47 0.00 0.15 0.52 0.00 0.03
005 0.00 0.00 0.00 0.00 0.00 0.00
006 0.54 0.00 1.65a 0.63 0.00 1.71
Cohort 3,
5.0  107 IP
007 0.55 0.00 0.00 0.41 0.00 0.00
008 0.00 0.09 0.14a 0.00 0.01 0.02
010 0.02 0.00 0.00 0.08 0.00 0.00
Cohort 4,
2.5  108 IP
011 0.02 1.00 0.36 0.00 0.00 0.01
012 0.08 0.61a 0.56a 0.05 0.00 0.20a
013 0.03 1.52a 0.57a 0.05 0.00 0.03
A, Before immunization; B, after two immunizations; C, after three immunizations. Note that responses at least 2-fold greater than the medium control were considered to be positive.
A positive vaccine-induced response was defined as at least a 3-fold higher percentage of antigen-specific proliferating Ki67+ T cells than that at pre-immunization.
aPositive vaccine-induced response.
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proliferation assay were collected after the 5-day culture and analyzed
for the production of various type 1/type 2/type 17 cytokines by cyto-
metric bead array.
There was an increase in the production of the type 1 cytokines, IFN-
g, and CXCL10, as detected in the culture supernatants. In 7 of 12
participants, a vaccine-induced HPV16 E6- and/or E7-specific pro-
duction of IFN-g was detected (Figure 4A). This IFN-g production
also coincided with the production of CXCL10. A vaccine-induced
HPV16 E6- and/or E7-specific production of CXCL10 was detected
in 5 of 12 participants (Figure 4B). Consistent with our previous find-
ings from IFN-g ELISPOT and Ki67 proliferation assays, we again
found a high production of IFN-g in the culture supernatants without
in vitro peptide restimulation, especially at the higher dosages of 5 
107 and 2.5  108 IP Vvax001. This level of IFN-g production was
only observed after immunization (time points B and C), and a
similar trend was found with CXCL10 production in the supernatants
from these participants. The production of type 2 cytokines such as
interleukin (IL)-4 and IL-10 did not increase upon Vvax001 immuni-
zation. A positive vaccine-induced increase in the production of IL-10
was detected only in participant 007, but the concentration of this
cytokine was still low (Figure S4C). The levels of cytokines tumor ne-
crosis factor (TNF)-a (Figure 4C), IL-17A, IL-1b, and transforming
growth factor (TGF)-b (Figures S4A, S4B, and S4D) varied upon im-
munization in a few participants. The levels of IL-2, IL-12, CCL2, and
CXCL8 did not vary with immunization.
Together with the IFN-g ELISPOT and Ki67 proliferation assays,
these results suggest that immunization with Vvax001 induced a
type 1 cytokine response, rather than a type 2/type 17 response.Vvax001 Elicited Production of Anti-vector Antibodies That Did
Not Abrogate Booster Responses
To investigate antibody responses against the SFV vector, serum sam-
ples from participants were assessed. No anti-SFV antibodies were
induced by the lowest dose of Vvax001 (5  105 IP) (Figure S5). In
the second dose (5  106 IP) group, in two out of three participants,
antibody titers after three immunizations were higher than the titers
before immunization. At the two highest doses of Vvax001 (5  107
and 2.5  108 IP), higher levels of anti-SFV antibodies were detected
both after the second and the third immunizations. Using a virus
neutralization assay, we demonstrated that the antibodies neutralized
SFV infection in BHK-21 cells in vitro (data not shown). Interestingly,
despite an increase in antibodies against SFV vector induced by the
vaccine, booster immunizations further enhanced the immune re-
sponses (as evaluated by IFN-g ELISPOT). This finding is similar
to our observations from preclinical studies, where we observed
that despite a reduction in transgene expression, passive transfer of
SFV neutralizing antibodies did not hinder cytolytic immune
responses.24
DISCUSSION
Herein, we report the results of a dose-escalating, phase I clinical
study of Vvax001, an rSFV-based therapeutic vaccine encoding a
fusion protein of HPV16 E6 and E7. This study shows that
Vvax001 is safe, well tolerated, and induced strong HPV16 E6- and
E7-specific immune responses. Even with the lowest dose of 5 
105 IP per immunization, Vvax001 was capable of inducing
HPV16-specific, IFN-g-producing T cells in all three participants in
this dose group. Vaccine-induced immune responses involved both
CD4+ as well as CD8+ T cells, and they were directed against both
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sponses. Overall, immunization resulted in positive, vaccine-induced
cellular immune responses in all participants in one or more assays
performed, at one or both time points post-immunization.
In extensive pre-clinical studies, we have shown that immuniza-
tion with SFVeE6,7 replicon particles induces strong and long-
lasting immune responses, leading to the complete elimination
of HPV-transformed tumors, even up to 6 months after immuni-
zation.12,13 Based on these promising results, we initiated this
first-in-human clinical trial of an SFV-based cancer vaccine to
study its tolerability and immunogenicity.12 Vvax001 was found
to be safe and well tolerated in these healthy female participants,
with only mild injection site reactions. There were no vaccine-
related grade 3 or 4 adverse events or dose-limiting toxicities at
all dosages tested. A similar safety was observed with vaccines
based on Venezuelan equine encephalitis (VEE) virus, the only
other alphavirus replicon particle-based vaccines that were evalu-
ated in clinical trials so far.25,26
IFN-g is not only a major effector molecule in anti-tumor immu-
nity, but also its bystander activity has been reported to promote
widespread and sustained cytokine signaling that could alter the
tumor microenvironment and help limit tumor growth.27 IFN-g
ELISPOT analysis demonstrated positive vaccine-induced HPV16
E6/E7-specific responses in 10 of 12 (83.3%) participants. The
E6/E7-specific IFN-g responses analyzed by ELISPOT were nega-
tive for participants 006 and 013, yet immunization did evoke an
E6- or E7-specific CD4+ T cell proliferative response in these par-
ticipants (Table 2). For participant 013, the lack of a vaccine-
induced E6/E7-specific response in the ELISPOT analysis could
be ascribed to the fact that the responses in the medium controls
at time points B and C were already high (see below). Participant
006 had a relatively high frequency of IFN-g-secreting cells
without E6/E7 peptide restimulation before immunization.
Notably, in all immune monitoring assays, i.e., IFN-g ELISPOT,
proliferation assays, and cytokine analysis, high IFN-g, prolifera-
tive, and cytokine responses, in PBMCs following immunization,
were found that did not require in vitro restimulation with E6
or E7 peptides. This was especially observed with the two higher
dosages of 5  107 and 2.5  108 IP per immunization. These
levels of IFN-g production in medium control cultures as well as
the rate of proliferation observed at these higher doses might be
ascribed to the presence of in vivo-activated T cells still present
in the blood samples that were collected 7–10 days following
immunization.Figure 3. Vvax001-Induced Proliferation of T Cells
PBMCs from before (time point A) and after immunizations (time points B and C) were an
of in vitro peptide restimulation. (A) Representative FACS plots of participant 012 (coho
especially CD4+ T cells, without peptide restimulation in vitro, along with the gating s
Percentages of (B) Ki67+CD4+ and (C) Ki67+ CD8+ T cells without in vitro peptide restimu
fold higher percentage of proliferating (Ki67+) T cells than that at pre-immunization.Due to the relatively high responses at higher dosages (two highest
doses) in the medium control, the calculated antigen-specific re-
sponses could be an underestimation of the response. Nonetheless,
the magnitude of the medium-corrected, HPV16-specific IFN-g-pro-
ducing T cell responses observed in our trial is at the same level or
even higher than that observed in two other clinical trials with
DNA vaccines, GX-188E and VGX-3100.28,29 In seven of nine
CIN3 patients included in the GX-188E trial, a complete regression
of lesion was established, which was attributed to vaccine-induced
E6- and E7-specific T cell responses and enhanced polyfunctional
CD8 T cell responses.28 VGX-3100 was the first therapeutic vaccine
against HPV to show efficacy in CIN 2/3 patients30 and is currently
in phase III clinical trial. In another trial with an HPV16 synthetic
long peptide vaccine, the magnitude of the frequency of vaccine-
induced HPV16-specific T cells producing IFN-g seemed to correlate
with clinical efficacy of the vaccine.31 In this respect and given the
potent HPV16-specific T cell responses shown in our clinical trial,
it will be of great interest to assess the therapeutic efficacy of
Vvax001 in future trials.
Persistence of HPV16 infection is associated with impaired CD4+ and
CD8+ T cell immunity and activity of both the T cell subsets is essen-
tial for anti-tumor responses.32–36 Vvax001 immunizations elicited
both CD4+ and CD8+ E6- and E7-specific T cell responses. The pro-
liferation assay shows a higher rate of proliferation of CD4+ T cells
compared to that of the CD8+ T cells. This high rate of CD4+ T cell
proliferation may likely further sustain CD8+ T cell responses. Both
CD4+ and CD8+ T cell responses are essential to generate a protective
immune response. CD4+ Th cells play an important role in the pro-
liferation and maintenance of effector functions of CD8+ T cells as
well as in the generation of memory CD8+ T cells.37–41 We demon-
strated that upon peptide restimulation both CD4+ and CD8+
T cells produce IFN-g (Figure 2). Furthermore, release of IFN-g
and CXCL10 in the whole PBMC cultures were upregulated, whereas
that of Th2 cytokines IL-4 and IL-10 were not. Increased levels of che-
mokines such as CXCL10 are associated with enhanced recruitment
of effector T cells to the tumor. Additionally, IFN-g along with IL-
12 and CXCL10 mediate anti-angiogenic effects. We also determined
changes in the levels of CXCL8 and CCL2, which are more relevant
for the recruitment of myeloid cells into the tumor microenviron-
ment. The levels of CXCL8 and CCL2 remained consistent before
and after immunization.42,43 A major concern often raised against
viral vector-based vaccines is the presence of either pre-existing anti-
bodies against the virus or vaccine-induced responses that may
impede booster responses against the transgenes. We previously
showed that upon immunization of mice with SFVeE6,7 replicon par-
ticles secondary (booster) immune responses against E6 and E7 arealyzed by flow cytometry (FACS) to determine the proliferating T cells in the absence
rt 4, 2.5  108 IP) showing the vaccine-induced, enhanced proliferation of T cells,
trategy used to determine proliferating (Ki67+) CD8+ and CD4+ T cells. (B and C)
lation are shown in these graphs. An asterisk indicates a response that is at least a 3-




Figure 4. Analysis of Cytokine Responses Induced by Vvax001
The polarization of vaccine-induced T cell responses was determined by measuring levels of Th1/Th2/Th17 cytokines in the culture supernatants from the proliferation assay
by cytokine bead array. Cells were stimulated with either HPV16 E6 (blue) or E7 peptide (green) pools for 5 days. Shown are the levels of pro-inflammatory cytokines (pg/mL):
(A) IFN-g, (B) CXCL10, and (C) TNF-a, before (time point A) and after immunization (time points B and C). The levels of cytokines in the controls (medium) are shown in white at
time point A, in gray at time point B, and in black at time point C. An asterisk indicates a positive vaccine-induced response (as defined in Materials and Methods).
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Cancers, Molecular Therapy (2020), https://doi.org/10.1016/j.ymthe.2020.11.002not disabled by vector-specific antibodies.24 Furthermore, passively
transferred SFV-neutralizing antibodies did not inhibit SFVeE6,7-
induced cytotoxic T lymphocyte (CTL) responses. We also demon-
strated that vector-specific T cell responses do not impede trans-
gene-specific responses as long as the host was primed with the ho-8 Molecular Therapy Vol. 29 No 2 February 2021mologous SFVeE6,7 vaccine. However, in mice initially primed
with SFV particles encoding a different transgene and then boosted
with SFVeE6,7, the induction of E6/E7-specific T cells was inhibited.
We hypothesized that this is due to T cell competition. As long as the
desired antigen is present during the prime immunization, T cell
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sponses.24,44 To circumvent the induction of vector-specific immu-
nity, alternative strategies are being studied by other groups and our-
selves on “naked” DNA and RNA vectors based on the replicase of
alphaviruses. Immunization with these non-viral vectors also effec-
tively elicit T cell and anti-tumor immune responses.1,45
We determined the vector-specific antibodies induced upon Vvax001
immunization. Also as expected, SFV-specific antibodies were
induced. While participants in the lowest dosage did not show
induction of SFV antibodies upon immunization, immunizations
with the higher dose levels induced SFV-specific neutralizing anti-
bodies. Nevertheless, similar to the mouse studies, the third
Vvax001 immunization resulted in increased E6/E7-specific immune
responses, even in five of six participants receiving the higher dose
levels. Similarly, in a phase I/II clinical trial using a VEE virus-based
vaccine expressing carcinoembryonic antigen (CEA) in patients with
metastatic cancer, immunizations resulted in CEA-specific T cell and
antibody responses, despite high titers of anti-vector neutralizing an-
tibodies.26 Also, in a phase II trial of TA-HPV, a live recombinant
vaccinia virus vaccine expressing modified forms of E6 and E7 pro-
teins of HPV16 and HPV18, immunization induced HPV16 E6-
and E7-specific T cell responses in six of eight clinical responders
while also immunoglobulin G (IgG) antibodies and T cell responses
against the vaccinia vector were induced.46
In clinical studies of tipapkinogen sovacivec (TG4001),47 SGN-
00101,48 and ZYC101a,49 it was noted that the clinical response
was not restricted to only those lesions with the HPV types whose
components were present in the vaccine. This could hint toward a
possible cross-protection among different high-risk HPV types.
Therefore, while designing future clinical studies of Vvax001,
which expresses fusion protein of HPV type 16-derived E6 and
E7, there might not be a need to restrict patients on the basis of
their HPV type status.
In conclusion, we demonstrate that Vvax001 is safe, well tolerated,
and immunogenic. Vvax001 was able to induce strong HPV16-spe-
cific IFN-g-producing CD4+ and CD8+ T cell responses. Further-
more, this study demonstrates that HPV16-specific T cell responses
are not impeded by homologous boost immunizations with
Vvax001 and that multiple immunizations are feasible and reinforce
the response. Although the number of participants is small, this study
gives an insight into the safety and immunogenicity of an SFV-based
vaccine, which has never been tested before in human participants
and warrants evaluation in a phase II trial to explore anti-tumor, ther-
apeutic efficacy.MATERIALS AND METHODS
Study Participants
The study population consisted of adult female participants with a
history of HPV-induced CIN 2 or 3, minimally 12 weeks after
completion of local surgical treatment.Additional inclusion criteria were as follows: adequate bone marrow
functions; HIV- and HBV-negative; and participants of child-bearing
potential should test negative using a serum pregnancy test and agree
to utilize effective contraception during the entire treatment and
follow-up period of the study. There was no restriction based on
HPV-status.
Exclusion criteria were as follows: prior treatment with immunother-
apeutic agents against HPV; history of an autoimmune disease or
other systemic intercurrent disease that might affect the immuno-
competence of the participant; current or prior use of high-dose
immunosuppressive therapy (4 weeks before start of the study); and
participation in a study with other investigational drugs within
30 days prior to the enrolment in this study.
The study was approved by the Central Committee on Research
Involving Human Participants (CCMO), the Dutch Ministry of
Health (The Hague, the Netherlands), and by the local ethics commit-
tee (METC, University Medical Center Groningen). Participants were
accrued from the outpatient clinic of the UMCG, the Netherlands.
Written informed consent to participate in the study was obtained
from all participants.
Vaccine
Three plasmids were constructed for the production of Vvax001 (Fig-
ure 5), using pSP6-SFV4: (1) pSFV3eE6,7 encoding the replicase and
E6,7 fusion protein, (2) pSFV-helper-C-S219A encoding the capsid
protein, and (3) pSFV-helper-S2 encoding the spike proteins. pSP6-
SFV4, pSFV-helper-C-S219A, and pSFV-helper-S2 were kind gifts
of P. Liljeström and C. Smerdou (Karolinska Institute, Stockholm,
Sweden). pSP6-SFV4 was constructed as previously described by Lil-
jeström and Garoff.4 The 26S subgenomic promoter in pSP6-SFV4
was replaced by a polylinker sequence for insertional cloning of
cDNA sequences under the 26S promoter, resulting in the so-called
pSFV3 vector. This pSFV3 vector was used as backbone for the inser-
tion of the HPV16 E6 and E7 fusion gene in the polylinker region. The
E6 and E7 genes were obtained from the plasmid pRSV-HPV16E6E7,
which was kindly provided by Dr. J. ter Schegget (University of Am-
sterdam, the Netherlands).50 A fusion protein of E6 and E7 was ob-
tained with the insertion of one base pair between E6 and E7, and
the stop codon of E6 changed from TAA to GAA. A translational
enhancer (the first 102 bases of the 50 end of the SFV capsid gene)
was inserted upstream of the gene encoding the E6,7 fusion protein
to increase recombinant gene expression.4 A sequence encoding for
the autoprotease 2A of foot-and-mouth disease virus was inserted
directly behind the enhancer for cleavage of the enhancer from the
E6,7 fusion protein.9 The pSP6-SFV4 was also modified for the helper
plasmids to encode the SFV capsid protein on one plasmid and the
envelope genes on the other.5
DNA of each individual plasmid was linearized via a digestion reac-
tion using the BcuI restriction enzyme (Fermentas; ER1251), which
has one recognition site in each plasmid. Linearized DNA was puri-
fied by ethanol precipitation. RNA was synthesized via in vitroMolecular Therapy Vol. 29 No 2 February 2021 9
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Figure 5. Plasmid Map of the Three Constructs
Used for the Production of the Vvax001 Replicon
Particles and Schematic Outline of the Trial
(A) Plasmid map of pSFV3eE6,7, pSFV-helper-C-S219A,
and pSFV-helper-S2. The first construct, A, encodes for
the SFV replicase and the fusion protein of HPV16 E6 and
E7. The constructs B andC are helper plasmids that code
for the SFV capsid protein and the envelope genes,
respectively. (B) The Vvax001 phase I clinical trial
included screening of participants for inclusion in the trial
(visit 1 [V1]); the Vvax001 immunizations at days 0, 21,
and 42 (visits V2, V3, and V5) are represented by bold
arrows and follow-up. Thin arrows represent the
collection of peripheral blood mononuclear cells (PBMCs)
for immune monitoring at baseline (V1; time point A)
and 7–10 days after the second (V4; time point B) and
third (V6; time point C) immunizations.
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promoter in each of the linearized DNA constructs. Next the RNA
was incubated with TURBO DNase to remove template DNA
(mMESSAGE mMACHINE kit Thermo Fisher Scientific; AM1340).
The purified RNA was recovered by lithium chloride precipitation
and centrifugation, and the resulting pellet was dissolved in
nuclease-free water. The purified RNA was tested for concentration,
purity, and endotoxins.
For the production of Vvax001,51 Vero cells (inlicensed from Intra-
vacc, Bilthoven, the Netherlands) were co-electroporated with the
three RNA transcripts. The recombinant replicon particles pro-
duced by transfected cells were then purified by chromatography10 Molecular Therapy Vol. 29 No 2 February 2021(BIA Separations, Ajdovscina, Slovenia). A vi-
rus titration assay was used to determine the
number of infectious particles per milliliter
(titer). The assay was performed by titration
of viral particles by serial dilution on mono-
layers of BHK cells. Infection by SFV particles
was determined by immunofluorescence using
a polyclonal rabbit anti-replicase (nsP3) anti-
body (kindly provided by Dr. T. Ahola, Hel-
sinki). Titers were calculated by counting pos-
itive cells and correction for the dilution
factor. The vaccine was diluted to the final
formulation as previously described.51 The
clinical grade Vvax001 was produced at the
Unit Biotech & ATMPs, Department of Clin-
ical Pharmacy and Pharmacology, UMCG, in
accordance with goodmanufacturing practices
(GMPs).
Vvax001 is a sterile suspension of replication-
deficient rSFV particles encoding a fusion pro-
tein of E6 and E7 of HPV type 16, containing
1.25  108 IP/mL in a buffer containing227 mM sodium chloride, 19 mM HEPES, and 1% human serum al-
bumin. The product was stored at 60C or lower. Vvax001 was
diluted with the same buffer (pH 7 ± 0.3) to prepare the first, second,
and third dose levels.
Trial Design
A standard 3+3 dose escalation design was used in which four dose
levels of Vvax001 were tested, i.e., 5  105, 5  106, 5  107, and
2.5  108 IP per immunization (Figure 5). Cohorts of three partici-
pants were treated per dose level; in total, 12 participants were
included. Enrollment of subsequent participants was continued
with a minimum interval of 48 h. Participants received three consec-
utive immunizations, with an interval of 3 weeks. Each dose was given
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per leg, in the m. vastus lateralis.
HPV Type-Specific PCR
The detection of HPV16 and other high-risk HPV genotypes was
performed as reported previously52 in our ISO-15189 accredited
laboratory. Two 20-mm sections were cut from paraffin-embedded
tissue biopsies of CIN lesions (in duplicate). After deparaffinization,
DNA isolation was performed using standard salt-chloroform extrac-
tion and ethanol precipitation. A hundred nanograms of this DNA
was analyzed by PCR for the presence of high-risk HPV, using
HPV16-specific primers as described previously.53 Both an HPV18-
specific PCR as well as a general HPV PCR using the HPV consensus
primer set GP5+/6+ with subsequent nucleotide sequence analysis
were used on all HPV16-negative cases.52,53
In all tests, a serial dilution of DNA extracted from CaSki (ATCC;
CRL1550; 500 integrated HPV16 copies), HeLa (ATCC; CCL2;
20–50 integrated HPV 18 copies), SiHa (ATCC; HTB35; 1–2 inte-
grated HPV16 copies), CC10B (HPV45-positive cell line), CC11
(HPV67-positive cell line), and HPV-negative cell lines were included
as control for the analytical specificity and sensitivity of each high-risk
HPV-PCR. The HPV16-specific PCR had a minimal analytical sensi-
tivity of 1:1,000 SiHa cells.
Contamination of amplification products was prevented by all
standard precautions, using separate laboratories for pre- and
post-PCR handling.52 Cross-contamination was prevented by using
a new microtome blade every time a new case was sectioned. Two
20-mm sections were cut from an empty paraffin block prior to
every tissue block and were analyzed in parallel with every case
as negative control to ensure that no cross-contamination had
occurred. For quality control, genomic DNA was amplified in a
multiplex PCR containing a control gene primer set resulting in
products of 100, 200, 300, 400, and 600 bp according to the BIO-
MED-2/Euroclonality protocol.54 Only DNA samples with PCR
products of 300 bp and larger were used for the detection of
HPV. All samples were tested on DNA extracted from two inde-
pendent slides (duplicates).
Safety and Tolerability Monitoring
Participants were evaluated before, during, and after immunization,
including history, physical examination, and toxicity scoring. Biochem-
istry was performed at baseline, prior to each immunization, and at
follow-up, including full blood count, urea, electrolytes, and liver func-
tion tests. Urine dipstick, electrocardiograph (ECG),HIV, and hepatitis
B virus (HBV) tests were performed at baseline. In case of child-bearing
potential, a pregnancy test was performed prior to each immunization.
Toxicity was graded according to the NCI Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.
Immunomonitoring
To assess the systemic changes in immunity induced by immuniza-
tion, PBMCs were obtained at baseline (time point A) and 7–10 days after the second and third immunizations (time points B
and C, respectively) and assessed using different immunological as-
says. Serum was isolated from clotting blood and cryopreserved.
PBMCs were isolated from fresh heparinized blood samples by Ficoll
(Ficoll Paque Plus; GE Healthcare, Uppsala, Sweden) density-
gradient centrifugation and cryopreserved in vapor phase nitrogen
until further experiments.
For all assays performed, cryopreserved PBMCs were thawed in
cold Iscove’s modified Dulbecco’s medium (IMDM) with Gluta-
MAX (Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with 10% fetal calf serum (PAA Laboratories, Pasching,
Austria) and 30 mg/mL DNase (Merck/Sigma-Aldrich, Darmstadt,
Germany). The cells were then rested overnight for at least 12 h
in IMDM, supplemented with 10% human AB serum (Sigma-Al-
drich), 100 U/mL penicillin (Thermo Fisher Scientific), 100 mg/
mL streptomycin (Thermo Fisher Scientific), and 50 mM b-mer-
captoethanol (Thermo Fisher Scientific) at 37C, 5% CO2.
For inclusion in the evaluation of the HPV16 E6/E7-specific
T cell responses (IFN-g ELISPOT), the participants had to fulfil
all of the following criteria: (1) the participant should have
received at least two doses of Vvax001; (2) the pre-immunization
blood sample should have a sufficient number of PBMCs (i.e.,
10  106); (3) the participant should have given at least one
blood sample after the second immunization and this blood sam-
ple should have a sufficient number of PBMCs (i.e., 10  106).
All participants receiving at least one dose of Vvax001 were
included in the safety evaluation. One participant (participant
009) was screened but did not receive any study medication, as
she withdrew due to personal circumstances.
Lymphocyte Subset Analyses
Cryopreserved and thawed PBMCs from all three time points were
analyzed for the presence of T cells, B cells, and NK cells. Cells
were stained with anti-CD3-allophycocyanin (APC) (clone SK7,
eBioscience, Waltham, MA, USA), anti-CD4-peridinin chlorophyll
protein (PerCP)-Cy5.5 (clone RPA-T4, BioLegend, London, UK),
anti-CD8-phycoerythrin (PE)-Cy7 (clone RPA-T8, BD Pharmingen,
San Jose, CA, USA), anti-CD19-fluorescein isothiocyanate (FITC)
(clone HIB19, BioLegend), and anti-CD56-Brilliant Violet 605 (clone
5.1H11, BioLegend), and analyzed on a BD FACSVerse.
IFN-g ELISPOT
Analysis of IFN-g-producing HPV16-specific T cells was done using
ELISPOT. Briefly, PBMCs were seeded at a density of 2  106 cells
per well in a 24-well plate (Corning, New York, NY, USA) in 1 mL
of IMDM supplemented with human AB serum. PBMCs were then
stimulated with 2 mg/mL of HPV16 E6-derived or E7-derived pep-
tide pools (15-mer with 11-aa overlap; JPT Peptide Technologies,
Berlin, Germany) for 3 days at 37C, 5% CO2. The CEF peptide
pool (JPT), consisting of human leukocyte antigen (HLA) class I-
restricted viral peptides from human cytomegalovirus (CMV), Ep-
stein-Barr virus (EBV), and influenza A virus (Flu), was used as aMolecular Therapy Vol. 29 No 2 February 2021 11
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After 3 days of culture, PBMCs were harvested, washed, and seeded
in four replicate wells, at a density of 1  105 cell per well in 100 mL
of X-VIVO 15 medium (Lonza, Geleen, the Netherlands) in a multi-
screen 96-well plate (Millipore), pre-coated with anti-human IFN-g
antibody (5 mg/mL in PBS; Mab-1-D1K; Mabtech, Nacka Strand,
Sweden). The cells in the fourth well within CEF control wells
were stimulated with phytohemagglutinin (PHA, 2 mg/mL, Thermo
Fisher Scientific) as a non-specific positive control. After 20–24 h,
the contents of the plate were discarded and the wells were washed
five times with washing buffer (0.05% Tween 20 [Sigma] in 1 PBS
[Gibco]). The wells were then incubated with biotinylated anti-hu-
man IFN-g antibody (0.3 mg/mL in PBS; Mab-7-B6-1; Mabtech) for
2 h in the dark at room temperature. The wells were washed with
washing buffer and incubated with ExtrAvidin-alkaline phosphatase
(ALP) (1:1,000 in PBS; Sigma-Aldrich) for 1 h in the dark at room
temperature. Next, 5-bromo-4-chloro-3-indolyl phosphate (BCIP)/
nitroblue tetrazolium (NBT)-ALP (Sigma) was added to the wells
and incubated for 5–20 min at room temperature to allow spot for-
mation. Incubation was stopped when staining in the controls
became apparent. The wells were then washed thoroughly with
tap water to stop the colorimetric reaction. The plates were then al-
lowed to dry overnight in the dark before counting the number of
developed spots by an ELISPOT reader (Autoimmun Diagnostika,
Strassberg, Germany). Specific spots were calculated by subtracting
the mean number of spots + 2  SD of the medium-only control
from the mean number of spots in experimental wells, expressed
as SFU (spot-forming units) per 106 PBMCs. Antigen-specific
T cell responses were considered to be positive when T cell fre-
quencies were R100 per 106 PBMCs. A vaccine-induced response
was defined as positive when at least a 3-fold increase in T cell fre-
quency was observed after immunization compared to before
immunization.55
To determine the contribution of CD4+ and CD8+ T cells to vaccine-
induced HPV16-specific T cell responses, the production of IFN-g by
these T cell subsets was determined by ELISPOT. PBMCs obtained
following immunization (time point B or C) were cultured for
3 days with or without peptide stimulation, as described above.
Following the 3-day incubation, cells were harvested and washed
with X-VIVO 15 medium, and then suspended in buffer (PBS con-
taining 0.5% BSA and 2 mM EDTA [pH 7.2]). First, CD8+ T cells
were isolated using CD8 MicroBeads (130-045-201; magnetic-acti-
vated cell sorting [MACS], Miltenyi Biotec, Leiden, the Netherlands)
and, subsequently, CD4+ T cells were isolated from the CD8 fraction
using CD4 MicroBeads (130-045-101; MACS, Miltenyi Biotec). The
magnetic separation was performed using an MS column (130-042-
201; MACS, Miltenyi Biotec), according to the manufacturer’s in-
structions. The purity of the sorted CD4+ and CD8+ T cell fractions
was in the range 88.2%–97.3% and 91.2%–99.8%, respectively, as as-
sessed by flow cytometry. Next, the CD4+ and CD8+ T cell fractions
were seeded at a density of 50,000 cells per well and cultured for 20-
24 h at 37C, 5% CO2. Thereafter, the ELISPOT assay was performed
as described earlier.12 Molecular Therapy Vol. 29 No 2 February 2021Proliferation Assay
The proliferative capacity of HPV16-specific T cells was determined
by a Ki67 proliferation assay. Thawed and overnight-rested PBMCs
were seeded at a density of 1.5  106 cells per tube and stimulated
with 2 mg/mL of HPV16 E6-derived or E7-derived peptide pools in
750 mL of IMDM supplemented with 10% human AB serum for
5 days at 37C, 5% CO2. The medium alone and CEF stimulation
served as negative and positive controls, respectively. At the end of
the 5-day culture, cells were washed (1,800 rpm, 5 min) with PBS
and subsequently stained for flow cytometric analysis. The cells
were first stained with Zombie Violet fixable viability dye (BioLegend)
for 30 min at room temperature in the dark. Next, the cells were
washed with FACS buffer (1 PBS supplemented with 5% fetal calf
serum [FCS]) and stained with anti-CD3-APC (clone SK7, eBio-
science), anti-CD4-PerCP-Cy5.5 (clone RPA-T4, BioLegend), anti-
CD8-PE-Cy7 (clone RPA-T8, BD Pharmingen), and anti-CD19-
FITC (clone HIB19, BioLegend) for 20 min. The cells were fixed
with reagent A (fixation reagent, FIX & PERM cell permeabilization
kit, Invitrogen) for 15 min in the dark at room temperature. After
washing with FACS buffer, the cells were permeabilized with reagent
B (permeabilization reagent). Following fixation and permeabiliza-
tion, cells were stained with anti-Ki67-PE (BD Pharmingen) for
30 min and then washed with FACS buffer. The cells were then resus-
pended in 250 mL of FACS buffer and analyzed on a BD FACSVerse.
Responses at least 2-fold greater than the medium control were
considered to be positive. A positive vaccine-induced response was
defined as at least a 3-fold higher percentage of antigen-specific prolif-
erating Ki67+ T cells than that at pre-immunization.
Cytokine Profile Analysis
Th1/Th2/Th17 cytokine production by HPV16-specific T cells was
measured in the supernatants isolated after the 5-day incubation in
the Ki67 proliferation assay by LEGENDplex (BioLegend). The hu-
man essential immune response panel contained beads for IL-4, IL-
2, CXCL10 (IP-10), IL-1b, TNF-a, CCL2 (MCP-1), IL-17A, IL-6,
IL-10, IFN-g, IL-12p70, CXCL8 (IL-8), and TGF-b1 (free active).
The assay was performed according to the manufacturer’s instruc-
tions, and the data were analyzed using the LEGENDplex data anal-
ysis software. Antigen-specific responses were considered to be posi-
tive when cytokine concentration was at least 2-fold greater than the
concentration of the medium control. A vaccine-induced response
was defined as at least a 3-fold increase in cytokine production than
at pre-immunization.28
Anti-SFV Antibody Analysis
Antibody titers against the SFV vector were quantified in the sera of
participants, at baseline and after the second and the third immuni-
zations. For this, 96-well ELISA plates with high binding capacity
(Greiner, Alphen a/d Rijn, the Netherlands) were coated with 5 
108 wild-type (WT)-SFV particles in 100 mL of coating buffer
(0.05 M carbonate-bicarbonate [pH 9.6–9.8]) per well and incubated
overnight at 4C. On the next day, the wells were washed with coating
buffer and blocked with blocking buffer (5% skimmedmilk powder in
1 PBS) overnight at 4C. Following blocking, the plates were washed
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samples were prepared by adding 75 mL of serum to 675 mL of serum
dilution buffer (2.5% skimmedmilk powder in washing buffer). These
serum samples were plated in triplicate, for each time point, and
sequentially diluted (2-fold dilutions). The plates were then incubated
for 1.5 h at 37C. Subsequently, the plates were washed three times
with washing buffer and incubated with goat-anti-human IgG-horse-
radish peroxidase (HRP) antibody (1:2,500 dilution in washing
buffer; SouthernBiotech, Birmingham, AL, USA) for 1 h at 37C.
The plates were then washed thrice with washing buffer and substrate
solution containing o-phenylenediamine dihydrochloride (OPD)
(SIGMAFAST OPD; Sigma) and hydrogen peroxide (Merck) was
added to the wells. Following incubation for 20 min, the staining re-
action was stopped with 2MH2SO4. The absorbance was measured at
492 nm. The dilution at which absorbance was greater than 0.2 was
used to deduce antibody titer.
Virus neutralizing activity of the sera was determined by titration of
2 108 IU of Vvax001, pretreated for 1 h at 37C with sera of partic-
ipants on monolayers of BHK cells and compared to the infectivity of
Vvax001 particles pretreated with control sera. Infectivity was deter-
mined by immunofluorescence using a polyclonal rabbit anti-repli-
case (nsP3) antibody (kindly provided by Dr. T. Ahola, Helsinki).
Statistical Analysis
No formal sample size calculation was performed. For all immuno-
monitoring assays, a positive vaccine-induced response was based
on predefined criteria as described above. Data obtained from flow cy-
tometry were analyzed using FlowJo software (Tree Star, Ashland,
OR, USA). All graphs were made with GraphPad Prism software
(version 8).
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